As filed with the Securities and Exchange Commission on November 7, 2000
                                                Registration No. 333-__________


                                  UNITED STATES
                       SECURITIES AND EXCHANGE COMMISSION
                             Washington, D.C. 20549


                                    FORM S-8
             REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933


                             MEDTOX SCIENTIFIC, INC.
             (Exact name of registrant as specified in its charter)

                                    Delaware
                 (State or other jurisdiction of incorporation)

                                   95-3863205
                      (I.R.S. Employer Identification No.)

402 West County Road D, St. Paul, Minnesota                         55112
(Address of principal executive offices)                         (Zip Code)


            MEDTOX Scientific, Inc. Restated Equity Compensation Plan
         MEDTOX Scientific, Inc. Qualified Employee Stock Purchase Plan
               MEDTOX Scientific, Inc. Non-Employee Director Plan
                            (Full title of the plans)


James B. Lockhart                   Copy to: Robert R. Ribeiro, Esq.
MEDTOX Scientific, Inc.                      Fredrikson & Byron, P.A.
402 West County Road D                       1100 International Centre
St. Paul, Minnesota 55112                    900 Second Avenue South
(651) 286-6225                               Minneapolis, Minnesota 55402
                                             (612) 347-7184
(Name, address and telephone number, including area code, of agent for service)

                         CALCULATION OF REGISTRATION FEE
                                                         Proposed
                                                         maximum
                                       Proposed maximum  aggregate  Amount of
 Title of securities    Amount to be   offering price    offering   registration
 to be registered       registered     per share (2)     price (2)  fee
 ----------------       ----------     --------------    ---------  ----------


Common Stock,par value   700,964(1)     $12.04           $8,439,606  $2,229.74
$0.15 per share

(1)  (a) Includes 560,964 shares available for issuance under the MEDTOX
         Scientific, Inc. Restated Equity Compensation Plan.
<PAGE>

     (b) Includes 125,000 shares issuable under the MEDTOX Scientific, Inc.
         Qualified Employee Stock Purchase Plan.

     (c) Includes 15,000 shares available for issuance under the MEDTOX
         Scientific, Inc. Non-Employee Director Plan.

         This  registration  statement  also  covers such  additional  number of
         shares  as may be  required  in  the  event  of a  stock  split,  stock
         dividend,  recapitalization,  reorganization,  merger, consolidation or
         other similar event.

(2)      Solely  for  the  purpose  of  calculating  the   registration  fee  in
         accordance with Rule 457(h)(1) and (c). The Proposed  Maximum  Offering
         Price Per Share and Proposed Maximum Aggregate Offering Price are based
         upon (i) with respect to 386,821  shares that may be acquired  pursuant
         to stock options  granted under the MEDTOX  Scientific,  Inc.  Restated
         Equity  Compensation  Plan,  and the 15,000 shares that may be acquired
         pursuant  to  options  granted  under  the  MEDTOX   Scientific,   Inc.
         Non-Employee  Director Plan,  the weighted  average price at which such
         stock  options may be  exercised,  (ii) with  respect to 28,444  shares
         issued  under the MEDTOX  Scientific,  Inc.  Qualified  Employee  Stock
         Purchase  Plan,  the weighted  average  price at which such shares were
         purchased,  and (iii) with respect to the remaining 288,199 shares that
         may be issuable from time to time after the date hereof under the three
         Plans,  $11.75 per share,  which represents the average of the high and
         low  prices of the  Common  Stock as  reported  on the  American  Stock
         Exchange on November 3, 2000.

<PAGE>


                                    PART II.
               INFORMATION REQUIRED IN THE REGISTRATION STATEMENT

Item 3.      Incorporation of Documents by Reference.
             ---------------------------------------

         The  following  documents  that we have filed with the  Securities  and
Exchange  Commission  are  incorporated  by  reference  into  this  registration
statement:

o        our annual report on Form 10-K for the year ended December 31, 1999;
o        our quarterly reports on Form 10-Q for the quarters ended March 31,
         2000 and June 30, 2000; and
o        the description of our common stock contained in our  registration
         statement  on Form 8-A and any  amendment  or report filed for the
         purpose of updating the description.

         All  documents  filed by us pursuant to Sections  13(a),  13(c),  14 or
15(d) of the  Securities  Exchange  Act of 1934  subsequent  to the date of this
registration  statement  and prior to the filing of a  post-effective  amendment
indicating that all securities offered by this registration  statement have been
sold, or deregistering all securities  remaining  unsold,  shall be deemed to be
incorporated  by reference in this  registration  statement  and to be a part of
this  registration  statement  from  the  respective  dates  of  filing  of such
documents.

Item 4.      Description of Securities.
             -------------------------

         Not applicable.

Item 5.      Interests of Named Experts and Counsel.
             --------------------------------------

         Not applicable.

Item 6.      Indemnification of Directors and Officers.
             -----------------------------------------

         Section 145 of the Delaware General Corporation Law ("DGCL") authorizes
a corporation's  board of directors to grant indemnity to directors and officers
in  terms   sufficiently   broad  to  permit   indemnification   under   certain
circumstances for liabilities  (including  reimbursement for expenses  incurred)
arising under the Securities Act.

         As permitted by the DGCL,  our  certificate of  incorporation  provides
that we shall  indemnify our  directors,  officers,  employees and agents to the
fullest extent  permitted by the DGCL. As permitted by the DGCL, our certificate
of  incorporation  also  includes  a  provision  that  eliminates  the  personal
liability of our  directors  for monetary  damages for breach of the  director's
fiduciary  duty,  except for liability (1) for any breach of the director's duty
of  loyalty to us or our  stockholders;  (2) for acts or  omissions  not in good
faith or that involve intentional  misconduct or a knowing violation of law; (3)
under Section 174 of the DGCL regarding  payments of dividends,  stock purchases
or redemptions  which are unlawful;  or (4) for any  transaction  from which the
director derived an improper personal benefit.

Item 7.      Exemption from Registration Claimed.
             -----------------------------------

         Not applicable.
<PAGE>

Item 8.      Exhibits.
             --------

         4.1      Medtox Scientific, Inc. Restated Equity Compensation Plan.

         4.2      Medtox Scientific, Inc. Qualified Employee Stock Purchase
                  Plan.

         4.3      Medtox Scientific, Inc. 1991 Non-Employee Director Plan.

         5.1      Opinion of Fredrikson & Byron, P.A.

         23.1     Consent of Deloitte & Touche LLP.

         23.2     Consent of Ernst & Young LLP

         23.3     Consent of Fredrikson & Byron, P.A. (contained in Exhibit 5.1
                  to this registration statement).

         24.1     Power of Attorney (included in the signature page of this
                  registration statement).

Item 9.      Undertakings.
             ------------

         (a)      The undersigned registrant hereby undertakes:

                  (1) To file,  during any  period in which  offers or sales are
         being made, a post-effective amendment to this registration statement:

                           (i)      To include any prospectus required by
                  Section 10(a)(3) of the Securities Act of 1933;

                           (ii) To reflect in the prospectus any facts or events
                  arising after the effective date of the registration statement
                  (or the most recent  post-effective  amendment thereof) which,
                  individually  or in the  aggregate,  represent  a  fundamental
                  change  in the  information  set  forth  in  the  registration
                  statement.  Notwithstanding  the  foregoing,  any  increase or
                  decrease in volume of securities  offered (if the total dollar
                  value  of   securities   would  not  exceed   that  which  was
                  registered)  and any deviation from the low or high end of the
                  estimated  maximum offering range may be reflected in the form
                  of  prospectus   filed  with  the   Securities   and  Exchange
                  Commission  pursuant to Rule 424(b) if, in the aggregate,  the
                  changes  in  volume  and  price  represent  no more than a 20%
                  change in the maximum  aggregate  offering  price set forth in
                  the "Calculation of Registration  Feel, table in the effective
                  registration statement; and

                           (iii)  To  include  any  material   information  with
                  respect to the plan of distribution  not previously  disclosed
                  in the  registration  statement or any material change to such
                  information in the registration statement;

         Provided,  however,  that paragraphs  (a)(1)(i) and (a)(1)(ii) above do
         not apply if  information  required to be included in a  post-effective
         amendment by those  paragraphs  is contained in periodic  reports filed
         with or furnished to the  Securities  and  Exchange  Commission  by the
         registrant  pursuant to Section 13 or Section  15(d) of the  Securities
         Exchange  Act  of  1934  that  are  incorporated  by  reference  in the
         registration statement.
<PAGE>

                  (2) That, for the purpose of determining  any liability  under
         the Securities Act of 1933, each such post-effective amendment shall be
         deemed to be a new  registration  statement  relating to the securities
         offered therein, and the offering of such securities at that time shall
         be deemed to be the initial bona fide offering thereof.

                  (3) To remove from  registration by means of a  post-effective
         amendment any of the securities being registered which remain unsold at
         the termination of the offering.

         (b) The undersigned  registrant hereby undertakes that, for purposes of
determining  any liability  under the Securities Act of 1933, each filing of the
registrant's  annual  report  pursuant to Section  13(a) or Section 15(d) of the
Securities  Exchange  Act of  1934  that is  incorporated  by  reference  in the
registration  statement  shall  be  deemed  to be a new  registration  statement
relating to the securities offered therein,  and the offering of such securities
at that time shall be deemed to be the initial bona fide offering thereof.

         (c)  Insofar  as  indemnification  for  liabilities  arising  under the
Securities Act of 1933 may be permitted to directors,  officers and  controlling
persons of the registrant  pursuant to the foregoing  provisions,  or otherwise,
the  registrant  has been  advised  that in the  opinion of the  Securities  and
Exchange  Commission such  indemnification is against public policy as expressed
in the  Securities  Act and is,  therefore,  unenforceable.  In the event that a
claim for  indemnification  against such liabilities  (other than the payment by
the  registrant  of expenses  incurred  or paid by a director,  officer or other
controlling  person of the registrant in the  successful  defense of any action,
suit or proceeding) is asserted by such director,  officer or controlling person
in connection with the securities being registered,  the registrant will, unless
in the  opinion  of its  counsel  the matter  has been  settled  by  controlling
precedent,  submit to a court of appropriate  jurisdiction  the question whether
such  indemnification  by it is  against  public  policy  as  expressed  in  the
Securities Act and will be governed by the final adjudication of such issue.

<PAGE>


                                   SIGNATURES

         Pursuant  to the  requirements  of the  Securities  Act  of  1933,  the
Registrant certifies that it has reasonable grounds to believe that it meets all
of the requirements for filing on Form S-3 and has duly caused this registration
statement  to be  signed  on its  behalf  by  the  undersigned,  thereunto  duly
authorized, in the City of St. Paul, State of Minnesota, on November 3, 2000.

                             MEDTOX Scientific, Inc.


                         By: /s/ Richard J. Braun
                             ---------------------------------------
                             Richard J. Braun
                             President, CEO and Director
                             (Principal Executive Officer)


                                POWER OF ATTORNEY

         Pursuant  to the  requirements  of the  Securities  Act of  1933,  this
Registration  Statement  has  been  signed  by  the  following  persons  in  the
capacities  and on the dates  indicated.  Each person  whose  signature  to this
Registration  Statement appears below hereby constitutes and appoints Richard J.
Braun and James B.  Lockhart,  and each of them,  as his or her true and  lawful
attorney-in fact and agent, with full power and substitution,  to sign on his or
her behalf individually and in the capacity stated below and to perform any acts
necessary  to be done  in  order  to  file  all  amendments  and  post-effective
amendments  to this  Registration  Statement,  and any  and all  instruments  or
documents filed as part of or in connection with this Registration  Statement or
the  amendments  thereto,  and each of the  undersigned  does hereby  ratify and
confirm all that said  attorney-in-fact  and agent,  or his or her  substitutes,
shall do or cause to be done by virtue hereof.

Signatures                  Title                             Date

  /s/ Richard J. Braun      President, CEO and Director       November 3, 2000
------------------------
Richard J. Braun


  /s/ James B. Lockhart     Vice President of Finance,        November 3, 2000
------------------------     Chief Financial Officer
James B. Lockhart            & Secretary


  /s/ Miles E. Efron         Director                         November 3, 2000
-----------------------
Miles E. Efron


  /s/ James W. Hansen        Director                         November 3, 2000
----------------------
James W. Hansen


  /s/ Brian Johnson          Director                         November 3, 2000
---------------------
Brian Johnson


<PAGE>

                                  EXHIBIT INDEX


       4.1      Medtox Scientific, Inc. Restated Equity Compensation Plan.

       4.2      Medtox Scientific, Inc. Qualified Employee Stock Purchase Plan.

       4.3      Medtox Scientific, Inc. 1991 Non-Employee Director Plan.

       5.1      Opinion of Fredrikson & Byron, P.A.

       23.1     Consent of Deloitte & Touche LLP.

       23.2     Consent of Ernst & Young LLP

       23.3     Consent of Fredrikson & Byron, P.A. (contained in Exhibit 5.1
                to this registration statement).

       24.1     Power of Attorney (included in the signature page of this
                registration statement).
[{"type": "S-8", "sequence": "1", "filename": "0001.txt", "description": "FORM S-8 REGISTRATION STATEMENT", "secsgml_size_bytes": 16138}]
{"company-data": {"conformed-name": "MEDTOX SCIENTIFIC INC", "cik": "0000739944", "assigned-sic": "2835", "irs-number": "953863205", "state-of-incorporation": "DE", "fiscal-year-end": "1231"}, "filing-values": {"form-type": "S-8", "act": "33", "file-number": "333-49456", "film-number": "754763"}, "business-address": {"street1": "402 WEST COUNTY ROAD D", "city": "ST PAUL", "state": "MN", "zip": "55112", "phone": "6126367466"}, "mail-address": {"street1": "402 WEST COUNTY ROAD D", "city": "ST PAUL", "state": "MN", "zip": "55112"}, "former-company": [{"former-conformed-name": "EDITEK INC", "date-changed": "19940902"}, {"former-conformed-name": "ENVIRONMENTAL DIAGNOSTICS INC", "date-changed": "19920703"}]}
As filed with the Securities and Exchange Commission on November 7, 2000
                                                Registration No. 333-__________

                                  UNITED STATES
                       SECURITIES AND EXCHANGE COMMISSION
                             Washington, D.C. 20549

                                    FORM S-8
             REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933

                             MEDTOX SCIENTIFIC, INC.
             (Exact name of registrant as specified in its charter)

                                    Delaware
                 (State or other jurisdiction of incorporation)

                                   95-3863205
                      (I.R.S. Employer Identification No.)

402 West County Road D, St. Paul, Minnesota                         55112
(Address of principal executive offices)                         (Zip Code)

            MEDTOX Scientific, Inc. Restated Equity Compensation Plan
         MEDTOX Scientific, Inc. Qualified Employee Stock Purchase Plan
               MEDTOX Scientific, Inc. Non-Employee Director Plan
                            (Full title of the plans)

James B. Lockhart                   Copy to: Robert R. Ribeiro, Esq.
MEDTOX Scientific, Inc.                      Fredrikson & Byron, P.A.
402 West County Road D                       1100 International Centre
St. Paul, Minnesota 55112                    900 Second Avenue South
(651) 286-6225                               Minneapolis, Minnesota 55402
                                             (612) 347-7184
(Name, address and telephone number, including area code, of agent for service)

                         CALCULATION OF REGISTRATION FEE
                                                         Proposed
                                                         maximum
                                       Proposed maximum  aggregate  Amount of
 Title of securities    Amount to be   offering price    offering   registration
 to be registered       registered     per share (2)     price (2)  fee
 ----------------       ----------     --------------    ---------  ----------

Common Stock,par value   700,964(1)     $12.04           $8,439,606  $2,229.74
$0.15 per share

(1)  (a) Includes 560,964 shares available for issuance under the MEDTOX
         Scientific, Inc. Restated Equity Compensation Plan.
(b) Includes 125,000 shares issuable under the MEDTOX Scientific, Inc.
         Qualified Employee Stock Purchase Plan.

     (c) Includes 15,000 shares available for issuance under the MEDTOX
         Scientific, Inc. Non-Employee Director Plan.

         This  registration  statement  also  covers such  additional  number of
         shares  as may be  required  in  the  event  of a  stock  split,  stock
         dividend,  recapitalization,  reorganization,  merger, consolidation or
         other similar event.

(2)      Solely  for  the  purpose  of  calculating  the   registration  fee  in
         accordance with Rule 457(h)(1) and (c). The Proposed  Maximum  Offering
         Price Per Share and Proposed Maximum Aggregate Offering Price are based
         upon (i) with respect to 386,821  shares that may be acquired  pursuant
         to stock options  granted under the MEDTOX  Scientific,  Inc.  Restated
         Equity  Compensation  Plan,  and the 15,000 shares that may be acquired
         pursuant  to  options  granted  under  the  MEDTOX   Scientific,   Inc.
         Non-Employee  Director Plan,  the weighted  average price at which such
         stock  options may be  exercised,  (ii) with  respect to 28,444  shares
         issued  under the MEDTOX  Scientific,  Inc.  Qualified  Employee  Stock
         Purchase  Plan,  the weighted  average  price at which such shares were
         purchased,  and (iii) with respect to the remaining 288,199 shares that
         may be issuable from time to time after the date hereof under the three
         Plans,  $11.75 per share,  which represents the average of the high and
         low  prices of the  Common  Stock as  reported  on the  American  Stock
         Exchange on November 3, 2000.
PART II.
               INFORMATION REQUIRED IN THE REGISTRATION STATEMENT

Item 3.      Incorporation of Documents by Reference.
             ---------------------------------------

         The  following  documents  that we have filed with the  Securities  and
Exchange  Commission  are  incorporated  by  reference  into  this  registration
statement:

o        our annual report on Form 10-K for the year ended December 31, 1999;
o        our quarterly reports on Form 10-Q for the quarters ended March 31,
         2000 and June 30, 2000; and
o        the description of our common stock contained in our  registration
         statement  on Form 8-A and any  amendment  or report filed for the
         purpose of updating the description.

         All  documents  filed by us pursuant to Sections  13(a),  13(c),  14 or
15(d) of the  Securities  Exchange  Act of 1934  subsequent  to the date of this
registration  statement  and prior to the filing of a  post-effective  amendment
indicating that all securities offered by this registration  statement have been
sold, or deregistering all securities  remaining  unsold,  shall be deemed to be
incorporated  by reference in this  registration  statement  and to be a part of
this  registration  statement  from  the  respective  dates  of  filing  of such
documents.

Item 4.      Description of Securities.
             -------------------------

         Not applicable.

Item 5.      Interests of Named Experts and Counsel.
             --------------------------------------

         Not applicable.

Item 6.      Indemnification of Directors and Officers.
             -----------------------------------------

         Section 145 of the Delaware General Corporation Law ("DGCL") authorizes
a corporation's  board of directors to grant indemnity to directors and officers
in  terms   sufficiently   broad  to  permit   indemnification   under   certain
circumstances for liabilities  (including  reimbursement for expenses  incurred)
arising under the Securities Act.

         As permitted by the DGCL,  our  certificate of  incorporation  provides
that we shall  indemnify our  directors,  officers,  employees and agents to the
fullest extent  permitted by the DGCL. As permitted by the DGCL, our certificate
of  incorporation  also  includes  a  provision  that  eliminates  the  personal
liability of our  directors  for monetary  damages for breach of the  director's
fiduciary  duty,  except for liability (1) for any breach of the director's duty
of  loyalty to us or our  stockholders;  (2) for acts or  omissions  not in good
faith or that involve intentional  misconduct or a knowing violation of law; (3)
under Section 174 of the DGCL regarding  payments of dividends,  stock purchases
or redemptions  which are unlawful;  or (4) for any  transaction  from which the
director derived an improper personal benefit.

Item 7.      Exemption from Registration Claimed.
             -----------------------------------

         Not applicable.
Item 8.      Exhibits.
             --------

         4.1      Medtox Scientific, Inc. Restated Equity Compensation Plan.

         4.2      Medtox Scientific, Inc. Qualified Employee Stock Purchase
                  Plan.

         4.3      Medtox Scientific, Inc. 1991 Non-Employee Director Plan.

         5.1      Opinion of Fredrikson & Byron, P.A.

         23.1     Consent of Deloitte & Touche LLP.

         23.2     Consent of Ernst & Young LLP

         23.3     Consent of Fredrikson & Byron, P.A. (contained in Exhibit 5.1
                  to this registration statement).

         24.1     Power of Attorney (included in the signature page of this
                  registration statement).

Item 9.      Undertakings.
             ------------

         (a)      The undersigned registrant hereby undertakes:

                  (1) To file,  during any  period in which  offers or sales are
         being made, a post-effective amendment to this registration statement:

                           (i)      To include any prospectus required by
                  Section 10(a)(3) of the Securities Act of 1933;

                           (ii) To reflect in the prospectus any facts or events
                  arising after the effective date of the registration statement
                  (or the most recent  post-effective  amendment thereof) which,
                  individually  or in the  aggregate,  represent  a  fundamental
                  change  in the  information  set  forth  in  the  registration
                  statement.  Notwithstanding  the  foregoing,  any  increase or
                  decrease in volume of securities  offered (if the total dollar
                  value  of   securities   would  not  exceed   that  which  was
                  registered)  and any deviation from the low or high end of the
                  estimated  maximum offering range may be reflected in the form
                  of  prospectus   filed  with  the   Securities   and  Exchange
                  Commission  pursuant to Rule 424(b) if, in the aggregate,  the
                  changes  in  volume  and  price  represent  no more than a 20%
                  change in the maximum  aggregate  offering  price set forth in
                  the "Calculation of Registration  Feel, table in the effective
                  registration statement; and

                           (iii)  To  include  any  material   information  with
                  respect to the plan of distribution  not previously  disclosed
                  in the  registration  statement or any material change to such
                  information in the registration statement;

         Provided,  however,  that paragraphs  (a)(1)(i) and (a)(1)(ii) above do
         not apply if  information  required to be included in a  post-effective
         amendment by those  paragraphs  is contained in periodic  reports filed
         with or furnished to the  Securities  and  Exchange  Commission  by the
         registrant  pursuant to Section 13 or Section  15(d) of the  Securities
         Exchange  Act  of  1934  that  are  incorporated  by  reference  in the
         registration statement.
(2) That, for the purpose of determining  any liability  under
         the Securities Act of 1933, each such post-effective amendment shall be
         deemed to be a new  registration  statement  relating to the securities
         offered therein, and the offering of such securities at that time shall
         be deemed to be the initial bona fide offering thereof.

                  (3) To remove from  registration by means of a  post-effective
         amendment any of the securities being registered which remain unsold at
         the termination of the offering.

         (b) The undersigned  registrant hereby undertakes that, for purposes of
determining  any liability  under the Securities Act of 1933, each filing of the
registrant's  annual  report  pursuant to Section  13(a) or Section 15(d) of the
Securities  Exchange  Act of  1934  that is  incorporated  by  reference  in the
registration  statement  shall  be  deemed  to be a new  registration  statement
relating to the securities offered therein,  and the offering of such securities
at that time shall be deemed to be the initial bona fide offering thereof.

         (c)  Insofar  as  indemnification  for  liabilities  arising  under the
Securities Act of 1933 may be permitted to directors,  officers and  controlling
persons of the registrant  pursuant to the foregoing  provisions,  or otherwise,
the  registrant  has been  advised  that in the  opinion of the  Securities  and
Exchange  Commission such  indemnification is against public policy as expressed
in the  Securities  Act and is,  therefore,  unenforceable.  In the event that a
claim for  indemnification  against such liabilities  (other than the payment by
the  registrant  of expenses  incurred  or paid by a director,  officer or other
controlling  person of the registrant in the  successful  defense of any action,
suit or proceeding) is asserted by such director,  officer or controlling person
in connection with the securities being registered,  the registrant will, unless
in the  opinion  of its  counsel  the matter  has been  settled  by  controlling
precedent,  submit to a court of appropriate  jurisdiction  the question whether
such  indemnification  by it is  against  public  policy  as  expressed  in  the
Securities Act and will be governed by the final adjudication of such issue.
SIGNATURES

         Pursuant  to the  requirements  of the  Securities  Act  of  1933,  the
Registrant certifies that it has reasonable grounds to believe that it meets all
of the requirements for filing on Form S-3 and has duly caused this registration
statement  to be  signed  on its  behalf  by  the  undersigned,  thereunto  duly
authorized, in the City of St. Paul, State of Minnesota, on November 3, 2000.

                             MEDTOX Scientific, Inc.

                         By: /s/ Richard J. Braun
                             ---------------------------------------
                             Richard J. Braun
                             President, CEO and Director
                             (Principal Executive Officer)

                                POWER OF ATTORNEY

         Pursuant  to the  requirements  of the  Securities  Act of  1933,  this
Registration  Statement  has  been  signed  by  the  following  persons  in  the
capacities  and on the dates  indicated.  Each person  whose  signature  to this
Registration  Statement appears below hereby constitutes and appoints Richard J.
Braun and James B.  Lockhart,  and each of them,  as his or her true and  lawful
attorney-in fact and agent, with full power and substitution,  to sign on his or
her behalf individually and in the capacity stated below and to perform any acts
necessary  to be done  in  order  to  file  all  amendments  and  post-effective
amendments  to this  Registration  Statement,  and any  and all  instruments  or
documents filed as part of or in connection with this Registration  Statement or
the  amendments  thereto,  and each of the  undersigned  does hereby  ratify and
confirm all that said  attorney-in-fact  and agent,  or his or her  substitutes,
shall do or cause to be done by virtue hereof.

Signatures                  Title                             Date

  /s/ Richard J. Braun      President, CEO and Director       November 3, 2000
------------------------
Richard J. Braun

  /s/ James B. Lockhart     Vice President of Finance,        November 3, 2000
------------------------     Chief Financial Officer
James B. Lockhart            & Secretary

  /s/ Miles E. Efron         Director                         November 3, 2000
-----------------------
Miles E. Efron

  /s/ James W. Hansen        Director                         November 3, 2000
----------------------
James W. Hansen

  /s/ Brian Johnson          Director                         November 3, 2000
---------------------
Brian Johnson
EXHIBIT INDEX

       4.1      Medtox Scientific, Inc. Restated Equity Compensation Plan.

       4.2      Medtox Scientific, Inc. Qualified Employee Stock Purchase Plan.

       4.3      Medtox Scientific, Inc. 1991 Non-Employee Director Plan.

       5.1      Opinion of Fredrikson & Byron, P.A.

       23.1     Consent of Deloitte & Touche LLP.

       23.2     Consent of Ernst & Young LLP

       23.3     Consent of Fredrikson & Byron, P.A. (contained in Exhibit 5.1
                to this registration statement).

       24.1     Power of Attorney (included in the signature page of this
                registration statement).